No data to show
XASX
IMR
Market cap210mUSD
Apr 08, Last price
1.19AUD
1D
0.00%
1Q
-6.30%
IPO
-3.25%
Name
Imricor Medical Systems Inc
Chart & Performance
P/E
—
P/S
342.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.27%
Rev. gr., 5y
-14.44%
Revenues
616k
-24.56%
Net income
-23m
L+29.04%
CFO
-20m
L+16.23%
Earnings
May 15, 2025
Profile
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 616 -24.56% | 816 17.20% | ||||||
Cost of revenue | 17,471 | 18,076 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (16,855) | (17,260) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 178 | |||||||
Tax Rate | ||||||||
NOPAT | (16,855) | (17,438) | ||||||
Net income | (22,626) 29.04% | (17,534) -14.70% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 5,848 | 4,301 | ||||||
BB yield | -6.55% | -7.83% | ||||||
| Debt | ||||||||
Debt current | 668 | 867 | ||||||
Long-term debt | 11,193 | 5,930 | ||||||
Deferred revenue | 727 | |||||||
Other long-term liabilities | 2,740 | 493 | ||||||
Net debt | 10,907 | 772 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (19,551) | (16,822) | ||||||
CAPEX | (83) | (239) | ||||||
Cash from investing activities | (83) | (239) | ||||||
Cash from financing activities | 8,214 | 3,943 | ||||||
FCF | (13,672) | (18,220) | ||||||
| Balance | ||||||||
Cash | 832 | 5,688 | ||||||
Long term investments | 122 | 338 | ||||||
Excess cash | 923 | 5,985 | ||||||
Stockholders' equity | (164,974) | 7,510 | ||||||
Invested Capital | 169,382 | 7,235 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 156,611 | 150,495 | ||||||
Price | 0.57 56.16% | 0.37 -63.68% | ||||||
Market cap | 89,268 62.51% | 54,931 -59.53% | ||||||
EV | 100,175 | 55,702 | ||||||
EBITDA | (16,855) | (16,548) | ||||||
EV/EBITDA | ||||||||
Interest | 48 | 178 | ||||||
Interest/NOPBT | ||||||||